// App-Quantinova.ai

: Long-Term Outcome of Low Dose of Anti-t-Lymphocyte Globulin in the Prophylaxis of Graft-Versus-Host Disease in Unrelated Myeloablative Hematopoietic Stem Cell Transplantation

Researchers

Presenter

  • Juan Manuel Cerezo

Principal Investigators

  • Maria Aranzazu Bermudez

  • David Martin Lorenzana

  • Sara Fenandez Luis

  • Lucrecia Yanez

  • Mercedes Colorado

  • Miriam Sánchez Escamilla

  • Iñigo Romón

  • Jose Luis Arroyo

  • Guillermo Martín Sánchez

  • Enrique M. Ocio

Medical Centers

  • Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain

  • Department of Hematology, University Hospital MarquéS De Valdecilla - IDIVAL, Santander, Spain

  • Hematology, Marques de Valdecilla University Hospital, Santander, Spain

  • Banco de Sangre y Tejidos de Cantabria, Santaner, Spain

  • Hospital Universitario Marqués de Valdecilla, Santander, ESP

  • University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • N/A

Drug/Treatment

  • EZ-2053

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved